Tripterygium preparations for the treatment of CKD: a systematic review and meta-analysis
- PMID: 23664549
- DOI: 10.1053/j.ajkd.2013.02.374
Tripterygium preparations for the treatment of CKD: a systematic review and meta-analysis
Abstract
Background: Preparations of the herb Tripterygium wilfordii Hook F are used widely for the treatment of chronic kidney disease in China. The efficacy and safety of Tripterygium preparations still have not been fully identified.
Study design: Systematic review and meta-analysis.
Setting & population: Patients with chronic kidney disease.
Selection criteria for studies: Randomized controlled trials.
Intervention: Tripterygium preparations (Tripterygium glycoside tablets, Tripterygium hypoglaucum Hutch tablets, and Tripterygium granules or extracts) versus placebo, standard care, or other immunosuppressive treatment.
Outcomes: Weighted mean difference and summary estimates of relative risk (RR) reductions with 95% CIs were calculated with a random-effects model. Outcomes analyzed included change in proteinuria, serum creatinine level, and creatinine clearance rate, as well as remission and relapse rate and drug-related adverse events.
Results: We identified 75 trials that included 4,386 participants. Overall, Tripterygium therapy reduced proteinuria by protein excretion of 628 (95% CI, -736 to -521) mg/d and reduced serum creatinine level by 0.12 (95% CI, -0.17 to -0.06) mg/dL compared with controls (both P < 0.001) in a range of kidney conditions. Tripterygium preparations also increased the rate of complete remission by 56% (95% CI, 32%-85%; P < 0.001) and of complete or partial remission by 24% (95% CI, 17%-31%; P < 0.001) while reducing relapse by 58% (95% CI, 42%-69%; P < 0.001). Tripterygium preparations increased the rate of liver function test result abnormalities (RR, 4.03; 95% CI, 2.24-7.25; P < 0.001) and altered menstruation (RR, 5.29; 95% CI, 2.09-13.38; P < 0.001).
Limitations: Suboptimal study quality, significant heterogeneity in the primary outcome.
Conclusions: Tripterygium preparations may have nephroprotective effects, but high-quality trials are required to reliably determine the balance of benefits and harms.
Keywords: Chinese herbs; Tripterygium; chronic kidney disease; glomerular disease; kidney function; meta-analysis; proteinuria; systematic review; traditional Chinese medicine.
Copyright © 2013 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Efficacy and safety of Tripterygium wilfordii Hook F for CKD in Mainland China: A systematic review and meta-analysis.Phytother Res. 2018 Mar;32(3):436-451. doi: 10.1002/ptr.5987. Epub 2017 Nov 28. Phytother Res. 2018. PMID: 29193402 Review.
-
Efficacy and safety of Tripterygium wilfordii hook F for chronic urticaria: a systematic review and meta-analysis.BMC Complement Altern Med. 2018 Aug 31;18(1):243. doi: 10.1186/s12906-018-2305-7. BMC Complement Altern Med. 2018. PMID: 30170584 Free PMC article. Review.
-
Efficacy and safety of Tripterygium wilfordii Hook. f. for oral lichen planus: Evidence from 18 randomized controlled trials.Phytother Res. 2020 Sep;34(9):2180-2191. doi: 10.1002/ptr.6672. Epub 2020 Mar 16. Phytother Res. 2020. PMID: 32180273
-
Tripterygium Glycosides for Treating Late-onset Rheumatoid Arthritis: A Systematic Review and Meta-analysis.Altern Ther Health Med. 2016 Nov;22(6):32-39. Altern Ther Health Med. 2016. PMID: 27866179 Review.
-
Meta-analysis of Tripterygium wilfordii Hook F in the immunosuppressive treatment of IgA nephropathy.Intern Med. 2010;49(19):2049-55. doi: 10.2169/internalmedicine.49.3704. Epub 2010 Oct 1. Intern Med. 2010. PMID: 20930429
Cited by
-
Colquhounia root tablet in the treatment of idiopathic membranous nephropathy with subnephrotic proteinuria.Int Urol Nephrol. 2024 Feb;56(2):699-706. doi: 10.1007/s11255-023-03682-2. Epub 2023 Jul 22. Int Urol Nephrol. 2024. PMID: 37480482
-
Network Pharmacology and Experimental Validation to Explore That Celastrol Targeting PTEN is the Potential Mechanism of Tripterygium wilfordii (Lév.) Hutch Against IgA Nephropathy.Drug Des Devel Ther. 2023 Mar 23;17:887-900. doi: 10.2147/DDDT.S402503. eCollection 2023. Drug Des Devel Ther. 2023. PMID: 36992900 Free PMC article.
-
Chitin powder enhances growth factor production and therapeutic effects of mesenchymal stem cells in a chronic kidney disease rat model.J Artif Organs. 2023 Sep;26(3):203-211. doi: 10.1007/s10047-022-01346-z. Epub 2022 Aug 17. J Artif Organs. 2023. PMID: 35976577
-
Differences in Multicomponent Pharmacokinetics, Tissue Distribution, and Excretion of Tripterygium Glycosides Tablets in Normal and Adriamycin-Induced Nephrotic Syndrome Rat Models and Correlations With Efficacy and Hepatotoxicity.Front Pharmacol. 2022 Jun 9;13:910923. doi: 10.3389/fphar.2022.910923. eCollection 2022. Front Pharmacol. 2022. PMID: 35754482 Free PMC article.
-
Triptolide promotes autophagy to inhibit mesangial cell proliferation in IgA nephropathy via the CARD9/p38 MAPK pathway.Cell Prolif. 2022 Sep;55(9):e13278. doi: 10.1111/cpr.13278. Epub 2022 Jun 22. Cell Prolif. 2022. PMID: 35733381 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
